Data sourced from Dakota Private Markets, the private fund performance platform powered by Dakota. Learn More | Request Access
$8B Curium Acquisition of Lantheus Signals the Maturation of Radiopharma as Institutional Capital's Newest Frontier
Curium US Holdings has agreed to acquire Lantheus Holdings for up to $8 billion, the largest transaction in radiopharmaceutical industry history. The deal signals a structural shift: nuclear medicine is no longer a fragmented specialty biotech niche but a consolidating, institutional-grade vertical spanning isotope production, diagnostics, and targeted therapy.
The announcement on August 3, 2026 pairs Curium's global manufacturing and theranostics pipeline with Lantheus' US radiodiagnostics franchise, the combination CapVest Partners (Curium's private equity owner) is betting will control the nuclear medicine supply chain end to end. The deal pays $102.50 per share in cash at closing plus contingent value rights worth up to $12.00 per share tied to sales milestones through 2030, for total potential consideration of $114.50 per share.
Dakota flagged the transaction in its August 2026 Private Funds Summary as health care's largest disclosed deal of the month, part of $36.9 billion in disclosed health care transaction value that Dakota tracked across pharmaceuticals, biotechnology, diagnostics, and life sciences services in August (Dakota Marketplace, 2026). The same report tracked the Lakers sale one sector over, in consumer discretionary, a reminder that institutional private capital is pricing sports franchises and radiopharmaceutical platforms off the same playbook.
That structure caps a year of consolidation across the radiopharmaceutical supply chain. Teledyne closed a $1.1 billion deal for Varex Imaging's detector and X-ray tube business, Radiology Partners paid $715 million for teleradiology group Everlight, and Align Capital Partners acquired 14-state mobile imaging platform Heritage Imaging, all in 2026. Curium-Lantheus is by far the largest of the group and the one drawing the most private capital attention.
Why CapVest Is Betting on Full Vertical Integration
The Curium-Lantheus combination reflects two forces reshaping how private capital approaches life sciences platforms. First: the shift from single-asset bets to supply chain control. Curium already runs 80-plus manufacturing sites across 70-plus countries; adding Lantheus' PYLARIFY (prostate cancer PET imaging), DEFINITY (cardiac ultrasound), and Neuraceq (beta-amyloid PET imaging) franchises gives CapVest a combined entity that controls production, distribution, and commercialization rather than one link in the chain.
Second: the rising premium on time-sensitive logistics. Radiopharmaceuticals decay on a clock, so scheduling, dose availability, and manufacturing continuity are the operating edge, not just the molecule. Curium's CEO called the tie-up an opportunity "neither company could achieve alone," and Lantheus' CEO framed it as combining "two pioneers with complementary strengths." Financial sponsors are underwriting operational integration in nuclear medicine the same way they have in radiology imaging platforms and specialty pharma manufacturing.
What the $8B Price Signals
The headline number understates how the deal is actually structured, and that structure is itself a signal. The $102.50 cash component represents a 38% premium to Lantheus' 60-day volume-weighted average price, a 29% premium to the 30-day average, and a 21% premium to the unaffected closing price as of May 21, 2026, before takeover speculation began.
The remaining $12.00 per share, roughly 10% of maximum deal value, arrives only if Lantheus hits specific commercial thresholds: prostate cancer diagnostics sales between $950 million and $1.75 billion, neurology diagnostics sales between $300 million and $350 million, and DEFINITY sales above $400 million, all measured through 2030. That is a buyer paying full price for the business it can underwrite today while making the seller re-prove the pipeline assets it has struggled to deliver on recently.
Risks and the Pipeline Squeeze
The contingent value rights exist because Lantheus' recent execution has been uneven. The FDA declined to approve LNTH-2501, its neuroendocrine tumor imaging kit, in June 2026 over manufacturing conditions, and Lantheus abandoned its PSMA-directed therapeutic program with Eli Lilly in 2025 after unfavorable Phase 3 data. A buyer paying $8 billion still wants exposure to that pipeline upside, but it wants the seller carrying the execution risk until the milestones prove out.
That is the CVR mechanic doing real work: it bridges a valuation gap between a buyer's caution on unproven assets and a seller's ambition for what those assets are worth. Expect the same structure to recur as more radiopharma and specialty diagnostics deals get done. Sellers with strong core franchises but unproven pipeline assets will increasingly get paid in installments, not upfront.
A Market Inflection
The Curium-Lantheus deal marks a structural inflection for nuclear medicine as an asset class. Radiology and radiopharma M&A is now visibly splitting into two tracks: upstream isotope production and radiopharmaceutical control (Curium-Lantheus, at up to $8 billion) and regional imaging capacity platforms serving underserved markets (Align Capital-Heritage Imaging's 14-state mobile rollup). Both tracks are attracting the same private capital that has spent the last several years consolidating radiology practices and diagnostic imaging equipment.
For fund managers, the message is direct: radiopharmaceuticals and nuclear medicine infrastructure are no longer a specialty biotech sub-sector. They are becoming a distinct life sciences infrastructure category, with financial sponsors like CapVest treating manufacturing scale and supply chain control as the primary value driver, not just the molecule pipeline. The next 12-18 months will likely bring more consolidation at both the isotope-production and regional-imaging-platform ends of the market as sponsors chase the same scarce, time-sensitive infrastructure.
.jpg)
